CTLA4 and renal cell carcinoma: Phs001493 (Renal cell carcinoma, Anti-PD1 therapy) and PRJEB23709_ipiPD1 (Melanoma,anti-CTLA4 & AMP; Anti-pd1 dual antibody therapy) were significantly associated with worse prognosis (see Additional file 2: Fig. S6B and D).